CD3 ScFvs as well as ScFvs specific for several tumor-associated cell surface antigens such as CD19, CD20, CD33, B-cell maturation antigen (BCMA), CD123, and CD38, as well as for tumor antigens identified in hematological malignancies [100,103], have been generated for clinical application [100,103]. This evidence concerns the gene TNFRSF17 and hematologic disorder.